During the MPN Hub Steering Committee meeting featuring John Mascarenhas, Steffen Koschmieder, Laura Michaelis, and Tiziano Barbui, Ruben Mesa discussed the use of momelotinib and luspatercept for the treatment of patients with myelofibrosis and anemia.

This educational resource is independently supported by GSK and Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.